Test Code HPVE6 Human Papillomavirus (HPV) High-Risk E6/E7, RNA In Situ Hybridization
Additional Testing Requirements
If additional interpretation or analysis is needed, request PATHC / Pathology Consultation along with this test.
Shipping Instructions
Attach the green "Attention Pathology" address label (T498) to the outside of the transport container before putting into the courier mailer.
Necessary Information
A pathology/diagnostic report and a brief history are required.
Specimen Required
Supplies: Pathology Packaging Kit (T554)
Specimen Type: Tissue
Container/Tube: Immunostain Technical Only Envelope
Collection Instructions: Formalin-fixed, paraffin-embedded tissue block; or 5 unstained glass, "positively charged" slides with 4-microns, formalin-fixed, paraffin-embedded tissue
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Oncology Test Request (T729)
-Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763)
Method Name
In Situ Hybridization (ISH)
Reporting Name
HPV E6/E7 ISHSpecimen Type
SpecialSpecimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Special | Ambient (preferred) | ||
Refrigerated |
Reject Due To
Wet/frozen tissue Cytology smears Nonformalin fixed tissue Nonparaffin embedded tissue Noncharged slides ProbeOn slides |
Reject |
Clinical Information
This assay is intended to identify the presence of human papillomavirus (HPV) E6/E7 transcripts from high-risk genotypes. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) have shown better disease-specific survival and overall survival when compared to HPV-negative cases of OPSCC. An indication for this test is p16 expression by immunohistochemistry.
Reference Values
Day(s) Performed
Monday through Friday
Report Available
5 to 7 daysPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88365-Primary
88364-If additional ISH